23 June 2020 The American Cancer Society estimates that as of January 2019 there were 16.9 million individuals in the United States living with a history of cancer, and 1.76 million newly diagnosed with cancer. Traditionally, patients return to their oncology team, primarily their medical oncologist, for follow up care after they complete active treatment. […]

7 June 2020 An abstract presented at last week’s virtual meeting of the American Society of Clinical Oncology focused on whether or not there is a benefit to surgery for the primary breast tumor in patients with metastatic, or Stage IV, breast cancer. Metastatic breast cancer (Met-BC) is when the breast cancer spreads beyond the breast and underarm […]

22 May 2020 Going Flat after mastectomy refers to not undergoing breast mound reconstruction after breast removal. Some patients are not candidates for reconstruction or it is not recommended, however many women may choose to “go flat” even when breast mound reconstruction is an option. This past October, we posted a research survey aimed at better […]

26 April 2020 A study published in the Annals of Internal Medicine addresses the use of screening mammography in older women*. The goal of screening mammography (performed on a woman with no suspicious abnormality) is to reduce the likelihood of death from breast cancer. However, there are no randomized studies demonstrating this benefit in older women […]

25 April 2020 I was asked to help the UCLA Jonsson Comprehensive Cancer Center team develop some infographics to help answer some common questions that patients with cancer may have regarding their treatment, office visits, and risk of infection. As always, good communication with your medical team is important – so reach out and ask […]

24 April 2020 A new drug was recently approved by the US Food and Drug Administration (FDA) for the treatment of metastatic breast cancer – breast cancer that has spread to other areas of the body, such as the bones, liver, lungs or brain. Sacituzumab govitecan (Trodelvy), which is given by intravenous infusion, was granted accelerated approval to […]

19 April 2020 The US Food and Drug Administration (FDA) has recently approved a new treatment for patients with metastatic breast cancer. Tucatinib (Tukysa) was approved for use in combination with 2 other agents, trastuzumab (Herceptin) and capecitabine (Xeloda) in patients with unresectable (too advanced to remove with surgery) or metastatic (spread to other areas of the […]